Biotechnology

Anti-viral and Anti-Inflammatory Response: GoldenBiotech's Antroquinonol Receives FDA Approval on COVID-19 Phase 2 Trial in USA

TAIPEI, July 1, 2020 /PRNewswire/ -- Golden Biotechnology Corp. (GoldenBiotech, 4132.TWO), a leading Taiwanese biopharmaceutical company, announced that the FDA approved its investigational new drug (IND) application for a Phase II clinical trial of Antroquinonol (Hocena®) on COVID-19 patients in...

2020-07-01 18:36 2939

Immvira Announces the Appointment of Carl Yeung as Chief Financial Officer

SHENZHEN, China, June 30, 2020 /PRNewswire/ -- Today Immvira Group Company (Immvira or the "Company"), a biotechnology company focused on the development of new generation oncolytic viruses as potential cancer therapeutics, announces the appointment ofCarl Yeung as Chief Financial Officer, report...

2020-07-01 08:30 2083

'Curing Cancer without Surgery'

* "Successful disappearance of tumors in subjects upon administering the pain-free anticancer drug, Polytaxel, without side effects such as weight loss." * Suppressed 99.8% of tumors despite a non-toxic dose…more effective than existing FDA-approved pancreatic cancer drugs. * Hopes for a Kore...

2020-06-30 15:10 1506

China Biologic Provides Additional Comments on the Xinjiang Deyuan and Shuanglin Transaction

BEIJING, June 29, 2020 /PRNewswire/ -- China Biologic Products Holdings, Inc. (NASDAQ: CBPO, "China Biologic" or the "Company"), a leading fully integrated plasma-based biopharmaceutical company inChina, today declared that the Company disagrees with the notice delivered by Xinjiang Deyuan Bioeng...

2020-06-29 13:00 11907

PharmAbcine Signs Long-term Contract Manufacturing Organization Agreement for Olinvacimab with Binex

DAEJEON, South Korea, June 26, 2020 /PRNewswire/ -- PharmAbcine (KRX: 208340) (CEO: Jin-san Yoo), biotech company focusing on the development of antibody therapeutics, announced on 18th that it had signed a contract manufacturing organization(CMO) agreement with biologics contract development ...

2020-06-27 00:00 1814

AUD$1.5M NHMRC Awards Grant to Expand Feasibility Trials for Stentrode, the First Interventional Neuromodulation Platform

Synchron's Stentrode brain-computer interface system is a fully-implantable therapeutic being evaluated for its safety and efficacy to restore functional independence via hands-free control of electronic devices in patients with upper limb paralysis SAN FRANCISCO and NEW YORK and MELBOURNE, June...

2020-06-25 10:10 2572

TurtleTree Labs raises US$3.2 million seed round as it accelerates cell-based milk development

SINGAPORE, June 24, 2020 /PRNewswire/ -- Singapore-based biotech company TurtleTree Labs today announced the completion of a fresh round of funding from global investors. TurtleTree Labs is the world's first-cell based biotechnology company creating real milk from mammalian cells, without the nee...

2020-06-25 08:00 2922

Global Cord Blood Corporation to Report Fourth Quarter and Full Year Fiscal 2020 Financial Results

HONG KONG, June 24, 2020 /PRNewswire/ -- Global Cord Blood Corporation (NYSE: CO) (the "Company"),China's leading provider of cord blood collection, laboratory testing, hematopoietic stem cell processing and stem cell storage services, today announced that it plans to release financial results fo...

2020-06-24 19:30 14515

Greater cfDNA Recovery May Help Accelerate Development of Cancer Liquid Biopsy Applications

GARDEN GROVE, Calif. , June 22, 2020 /PRNewswire/ -- PHASE Scientific, a high-growth biotechnology company that develops innovative sample preparation technologies, announced new findings at the American Association for Cancer Research (AACR) 2020 Virtual Annual Meeting II. The study presented by...

2020-06-22 21:00 1274

Reistone Announces First Patient Dosed in a Phase II Global Study of SHR0302 JAK Inhibitor for Alopecia Areata

SHANGHAI, June 18, 2020 /PRNewswire/ -- Reistone Biopharma Company Limited (Reistone), a clinical stage biopharmaceutical company focused on developing novel medicines for autoimmune and inflammatory diseases, today announced dosing of the first patient in their Phase II, global clinical trial (R...

2020-06-19 09:16 1243

Immunexpress Awarded BARDA Contract to Develop SeptiCyte® RAPID for COVID-19 Patient Triage

SEATTLE, June 16, 2020 /PRNewswire/ -- Immunexpress, Inc., a molecular diagnostic company focused on improving outcomes for suspected sepsis patients, has been awarded a grant from the Biomedical Advanced Research and Development Authority ("BARDA"), part of the Office of the Assistant Secretary ...

2020-06-16 20:00 1041

ImmVira Raises $58M in Series B financing

SHENZHEN, China, June 15, 2020 /PRNewswire/ -- Today Immvira Group Company, a biotechnology company focused on the development of new generation oncolytic viruses as potential cancer therapeutics, announces the completion of Series B financing for58 million US dollars. Attracting some of the top ...

2020-06-15 20:00 1326

I-Mab and ABL Bio to Present Preclinical Data for Joint Bispecific Antibody Program at the 2020 American Association for Cancer Research Virtual Meeting II

SHANGHAI and GAITHERSBURG, Md., June 12, 2020 /PRNewswire/ -- I-Mab (the "Company") (Nasdaq: IMAB), a clinical stage biopharmaceutical company committed to the discovery, development and commercialization of novel biologics, will be presenting preclinical data on a newly developed, novel asset TJ...

2020-06-12 20:00 7083

World's first iLDC enabling ADC drug receives IND clearance by the US FDA

SUZHOU, China, June 11, 2020 /PRNewswire/ -- GeneQuantum Healthcare (GQ) has recently received the US IND approval for its in-house developed next generation antibody drug conjugate (ADC) asset, GQ1001. This isthe world's first site-specific ADC produced using the intelligent ligase-dependent co...

2020-06-11 17:10 1169

ChemPartner Makes Additional Investments in Biologics from Research to Manufacturing Capabilities

SHANGHAI, June 10, 2020 /PRNewswire/ -- Shanghai ChemPartner announced the additional investments the company is making into its biologics business unit to further its capabilities and capacity in biologics discovery through development and manufacturing. "ChemPartner has rich experience in prov...

2020-06-10 23:03 1439

CellResearch Corporation - Source of cGMP Umbilical Cord Lining Stem Cells for COVID-19 Related Investigator Initiated Clinical Trials

SINGAPORE, June 10, 2020 /PRNewswire/ -- CellResearch Corporation (CellResearch), a regenerative medicine biotechnology company, is making its cGMP-grade umbilical cord lining stem cell product, CorLiCyte®, available complimentary to any licensed medical institution that is seeking to initiat...

2020-06-10 21:00 1084

Collaborating in Innovative Medical R&D to combat the pandemic, Alphamab Oncology and Institut Pasteur Shanghai Announce Partnership to Co-develop COVID-19 Neutralizing Antibody

SUZHOU, China, June 9, 2020 /PRNewswire/ -- Alphamab Oncology (stock code: 9966 HK) announced that Jiangsu Alphamab Biopharmaceuticals Co., Ltd. ("Jiangsu Alphamab"), a wholly-owned subsidiary of the Company, has entered a partnership agreement with Institut Pasteur ofShanghai, Chinese Academy of...

2020-06-10 08:40 5923

Alphamab Oncology and Sanofi Enter Collaboration on KN026 in HER2+ Breast Cancer

SUZHOU, China, June 8, 2020 /PRNewswire/ -- Alphamab Oncology (stock code: 9966 HK) a clinical stage biopharmaceutical company focusing on innovative biologics medicine for oncology, and Sanofi (EURONEXT: SAN and NASDAQ: SNY), a global biopharmaceutical leader, announced today that Jiangsu Alpham...

2020-06-09 10:10 5826

Innovent and Roche Enter into A Strategic Collaboration to Discover and Develop Multiple Products including Cellular Therapies and Bispecific Antibodies

SUZHOU, China, June 8, 2020 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for the treatment of cancer, metabolic, autoimmune and other major diseases, today announ...

2020-06-09 07:30 1833

Antengene Corporation Appoints Mr. Donald Lung as Chief Financial Officer

SHANGHAI and HONG KONG, June 8, 2020 /PRNewswire/ -- Antengene Corporation (Antengene) today announced its appointment of Mr.Donald Lung as Chief Financial Officer (CFO), effectiveJune 8, 2020. Donald will report directly to Dr.Jay Mei, Chairman and CEO of Antengene.

2020-06-08 20:00 2236
1 ... 120121122123124125126 ... 129